CG Oncology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from CG Oncology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 2,015% in 3 years, but profit fell: $3,262 less profit per $100 of extra sales. Lower than 98% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 0/3Sales grew in 3 of the last 3 years; profit grew in 0 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$3,262Sales grew 2,015% in 3 years, but profit fell: $3,262 less profit per $100 of extra sales.
Lower than 98% of Healthcare companies in United States.
Asset Productivity Ratio
+2015% / +436%In 3 years sales changed by +2015% while total assets changed by +436%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-144.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 88% of Healthcare companies in United States.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 55% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 87% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
CG Oncology, Inc. made a loss over the last year. CG Oncology, Inc. owes $0.05 for every $1 it owns. CG Oncology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCG Oncology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.32The share price is 5.32 times CG Oncology, Inc.'s book value per share, higher than 74% of Healthcare companies in United States.
Market cap
$5.5 BThe total market value of all of CG Oncology, Inc.'s shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.0 BWhat CG Oncology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.61Net worth divided by the number of shares. The share price of $61.71 is 5.3 times this, which is the P/B above.
Return on equity (ROE)
-26.4%CG Oncology, Inc. lost 26.4% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
Owes vs Owns
0.05×CG Oncology, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneCG Oncology, Inc. does not currently pay a dividend.
Revenue growth
+255%Revenue rose 255% in the year to Dec 2025, and grew 177% a year on average over 3 years.
Profit growth
LossCG Oncology, Inc. made a loss in each of the last two years.
Profit margin
-3985.0%CG Oncology, Inc. lost $3985 for every $100 of revenue.
Cash vs debt
Net cashCG Oncology, Inc. held $735 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For CG Oncology, Inc.: $5.5 B ÷ $1.0 B (30 Jun 2026) = 5.3.
What is CG Oncology, Inc.'s return on equity?
CG Oncology, Inc. lost 26.4% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
How much does CG Oncology, Inc. owe compared with what it owns?
CG Oncology, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does CG Oncology, Inc. pay a dividend?
No. CG Oncology, Inc. does not currently pay a dividend.
Is CG Oncology, Inc.'s revenue growing?
Revenue rose 255% in the year to Dec 2025, and grew 177% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.